Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Drug
The First People's Hospital of Lianyungang
Herpes Zoster
1 trial -
Drugs and Stimulation
The First People's Hospital of Lianyungang
Hearing Loss, Sudden
1 trial -
Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
The First People's Hospital of Lianyungang
Diabetes
1 trial -
Dynamometric tension assessment
The First People's Hospital of Lianyungang
Incisional Hernia
1 trial -
EPCs plus PTA
The First People's Hospital of Lianyungang
Diabetic Foot
1 trial -
Efgartigimod + Telitacicept (1-week interval) group
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Entecavir 0.5 mg
The First People's Hospital of Lianyungang
Hepatitis B
1 trial -
Escitalopram Oxalate Tablets
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Postoperative Cognitive Dysfunction
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Post Induction Hypotension
1 trial -
Esketamine at low dose
The First People's Hospital of Lianyungang
Insomnia
1 trial -
Experimental group
The First People's Hospital of Lianyungang
Overweight or Obesity
1 trial -
Favipiravir
The First People's Hospital of Lianyungang
COVID-19
1 trial -
Febuxostat
The First People's Hospital of Lianyungang
Refractory Gout
1 trial -
Fei Re Qing Granules
The First People's Hospital of Lianyungang
Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection
1 trial -
Forced administration of furosemide
The First People's Hospital of Lianyungang
Cytoreductive Surgery
1 trial -
Fruquintinib and Everolimus
The First People's Hospital of Lianyungang
Renal Cell Carcinoma, Clear Cell, Somatic
1 trial -
G-CSF (Granulocyte colony-stimulating factor)
The First People's Hospital of Lianyungang
Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization
1 trial -
GD007 Low-dose drug group
The First People's Hospital of Lianyungang
Moderate-Severe Intrauterine Adhesions
1 trial -
GDMT
The First People's Hospital of Lianyungang
Heart Failure With Preserved Ejection Fraction
1 trial -
Gastrodin Injection
The First People's Hospital of Lianyungang
Sensorineural Hearing Loss
1 trial -
Gemcitabine, cisplatin
The First People's Hospital of Lianyungang
Bladder Cancer
1 trial -
Ginkgo Biloba Extract
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
GnRH-a
The First People's Hospital of Lianyungang
Clinical Pregnancy Rate
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources